Reply to the Letter to the Editor: “Anti-inflammatory role of lipoprotein apheresis in the era of small interfering RNA inhibitor of apolipopritein(a)”
placebo-controlled randomized trials assessing its effect on the incidence of cardiovascular events are still lacking.Consequently, any possible pleiotropic and potentially antiinflammatory effects of apheresis treatment can neither be excluded nor proven at this time.
Authors
- Winfried März (ORCID: https://orcid.org/0000-0001-6083-8946)
- Hubert Scharnagl (ORCID: https://orcid.org/0000-0002-2750-006X)
- Marcus E. Kleber (ORCID: https://orcid.org/0000-0003-0663-7275)
- Stephanie Wissel (ORCID: https://orcid.org/0009-0004-1625-6956)
- Angela P. Moissl (ORCID: https://orcid.org/0000-0003-0302-2136)
- Bernhard Krämer
- Graciela Delgado
Institutions
- Goethe University Frankfurt (DE)
- Synlab Czech (Czechia) (CZ)
- Medical University of Graz (AT)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Synlab (Germany) (DE)
- University Hospital Frankfurt (DE)
- University Medical Centre Mannheim (DE)
- Heidelberg University (US)
Publication Details
- Journal
- Clinical Research in Cardiology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1007/s00392-025-02807-0
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00